Premium
THE EFFECT OF IPRONIAZID AND IMIPRAMINE ON THE BLOOD PLATELET 5‐HYDROXYTRYPTAMINE LEVEL IN MAN
Author(s) -
MARSHALL ELIZABETH F.,
STIRLING G. S.,
TAIT A. C.,
TODRICK A.
Publication year - 1960
Publication title -
british journal of pharmacology and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0366-0826
DOI - 10.1111/j.1476-5381.1960.tb01207.x
Subject(s) - imipramine , iproniazid , platelet , serotonin , endocrinology , pharmacology , medicine , chemistry , hydrochloride , monoamine oxidase , biochemistry , enzyme , alternative medicine , receptor , pathology
Observations are reported on the blood platelet 5‐hydroxytryptamine content of six patients receiving imipramine, N ‐(γ‐dimethylaminopropyl)‐iminodibenzyl hydrochloride. The response was a fall to a level of one‐sixth of the original in three weeks, with little change thereafter. This is in sharp contrast to the action of iproniazid which caused a rise of some 200% in the blood platelet 5‐hydroxytryptamine level over the same period. Imipramine in a concentration of 1 mg./ml. had no inhibitory action on 5‐hydroxytryptophan decarboxylase; 8·0 μg./ml. of imipramine suppressed two‐thirds of the in vitro uptake of 5‐hydroxytryptamine (2·5 μg./ml.) by normal human platelets.